710623Further Development of an Anti-EGFR Bispecific Antibody for Metastatic Colorectal Cancer and a Platform AssetClosedGRD Proof of ConceptInnovate UKShyDen Biotechnology is a start-up antibody drug discovery company based in the Open Innovation incubator, The Stevenage Bioscience Catalyst. It is discovering and developing the next generation of bispecific antibodies that can be switched on or off, thus carrying a new level of molecular regulation and thus safety. This project is to extend our work and build on the success from a previous SMART award to further develop our prototype as well as derive a more valuable platform technology to discover further product candidates. This will be aimed at metastatic colorectal cancer, but later other solid cancers could be targeted.